Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Assets (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Assets for 16 consecutive years, with $159.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 27.26% to $159.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $159.4 million, a 27.26% increase, with the full-year FY2024 number at $125.4 million, up 7.61% from a year prior.
  • Assets was $159.4 million for Q3 2025 at Gyre Therapeutics, up from $152.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $159.4 million in Q3 2025 to a low of $10.0 million in Q3 2023.
  • A 5-year average of $88.8 million and a median of $101.8 million in 2021 define the central range for Assets.
  • Peak YoY movement for Assets: plummeted 85.13% in 2023, then surged 1156.92% in 2024.
  • Gyre Therapeutics' Assets stood at $55.7 million in 2021, then skyrocketed by 52.26% to $84.8 million in 2022, then surged by 37.5% to $116.5 million in 2023, then rose by 7.61% to $125.4 million in 2024, then increased by 27.09% to $159.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Assets are $159.4 million (Q3 2025), $152.6 million (Q2 2025), and $129.8 million (Q1 2025).